SLC5A2 and diabetes mellitus: The use of insulin among diabetes patients remained stable through the study period, the use of beta cell stimulating agent fell, while the use of Metformin, Glucagon-like peptide-1 analogs, Dipeptidyl peptidase-4 inhibitors, and Sodium Glucose Cotransporter 2 inhibitors rose (Online Resource Table 3).